1 / 18

Laryngeal Cancer

Laryngeal Cancer. Clerk 2: 吳柏宣 陳昱潔 Supervisor: 李家和醫師. Anatomy. Anatomy. Vaezi, MF . Nature Clinical Practice Gastroenterology & Hepatology (2005) 2 , 595-603. Anatomy– Supraglottic larynx. It consists of epiglottis, false vocal cords, ventricles, aryepiglottic folds, and arytenoids.

ksmallwood
Download Presentation

Laryngeal Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Laryngeal Cancer Clerk 2: 吳柏宣 陳昱潔Supervisor: 李家和醫師

  2. Anatomy

  3. Anatomy Vaezi, MF . Nature Clinical Practice Gastroenterology & Hepatology (2005) 2, 595-603

  4. Anatomy– Supraglottic larynx • It consists of epiglottis, false vocal cords, ventricles, aryepiglottic folds, and arytenoids

  5. Anatomy– Glottic larynx • It consists of the true vocal cords and anterior commissure and posterior commissure

  6. Anatomy– Subglottic larynx • It consists of the region between the vocal cords and the trachea.

  7. Epidemiology • Male : Female = 4 : 1 • Age: 50~60 y/o • > 90% squamous cell cancer • 位置分類 • Glottic cancer80% • Supraglottic cancer20% • Subglottic cancer1%

  8. Risk Factors Smoking(最主要危險因子)。 Alcohol(有加成作用)。 HPV type16 and 18 GERD。 長期暴露於石棉、芥子氣 、石化氣體

  9. Clinical Presentation • Mass effect: hoarseness, dysphagia, hemoptysis, neck mass, airway compromise (difficulty breathing), aspiration • Throat pain, ear pain (referred through CN X branch) • Suggests advanced stage • Hoarseness = allow for early detection of glottic cancer • Weight loss

  10. Clinical Presentation – cont’ • Physical Exam • Complete head and neck exam • Palpation for nodes; restricted laryngeal crepitus. • Quality of voice • Breathy voice = cord paralysis • Muffled voice = supraglottic lesion • Laryngoscopy • Stroboscopic video laryngoscopy

  11. Staging • Glottis • Tis: CA in-situ • T1: limited to cord; • T1a: one cord; T1b: two cords • T2: extends to supraglottis, and/or subglottis, and/or w/impaired cord mobility • T3: limited to larynx w/vocal cord fixation and/or invades paraglottic space, and/or minor thyroid cartilage erosion • T4a: invades thyroid cartilage and/or tissues beyond larynx • T4b: invades prevertebral space, encases carotid artery, or invades mediastinal structures • Subglottis • T1: limited to subglottis • T2: extends to vocal cord with normal or impaired mobility • T3: limited to larynx w/vocal cord fixation • T4a: invades cricoid or thyroid cartilage, and/or invades tissues beyond the larynx • T4b: invades prevertebral space, encases carotid artery, or invades mediastinal structures • Supraglottis • T1: limited to subsite of supraglots w/normal cord mobility • T2: invade mucosa of > 1 subsite of supraglottis, glottis, or outside of supraglottis w/out fixation of the larynx • T3: limited to larynx w/vocal cord fixation and/or invades postcricoid area, pre-epiglottic tissues, paraglottic space, and/or minor thyroid cartilage erosion • T4a: invades thyroid cartilage and/or tissues beyond larynx • T4b: invades prevertebral space, encases carotid artery, or invades mediastinal structures

  12. Staging • Subglottis • Tis: CA in-situ • T1: limited to subglottis • T2: extends to vocal cord with normal or impaired mobility • T3: limited to larynx w/vocal cord fixation • T4a: invades cricoid or thyroid cartilage, and/or invades tissues beyond the larynx • T4b: invades prevertebral space, encases carotid artery, or invades mediastinal structures • Nodes • N0: no regional node mets • N1: single ipsilateral node, ≤ 3 cm • N2a: single ipsilateral node, > 3 cm, ≤ 6 cm • N2b: multiple ipsilateral nodes, ≤ 6 cm • N2c: bilateral or contralateral nodes, ≤ 6 cm • N3: node > 6 cm • Mets • Mx: unknown • M0: no distant mets • M1: distant mets

  13. Stage Grouping Early stage Advanced stage

  14. Treatment – Early Stage (I/II) • Early stage (T1 and T2) can be treated with radiotherapy or surgery (endoscopic resection or open organ-preservation surgery) alone, both offer the 85-95% cure rate. • Surgery has a shorter treatment period, saves radiation for recurrence, but may have worse voice outcomes • Radiotherapy is given for 6-7 weeks, avoids surgical risks but has own complications

  15. Treatment – Early stage (I/II) • XRT complications include: • Mucositis • Odynophagia • Laryngeal edema • Xerostomia • Stricture and fibrosis • Radionecrosis • Hypothyroidism

  16. Treatment – Advanced Stage (III/IV) • Advanced stage lesions often receive surgery with adjuvant radiation • Most T3 and T4 lesions require a total laryngectomy • Some small T3 and lesser sized tumors can be treated with partial larygectomy

  17. Treatment – Advanced Stage (III/IV) • Chemotherapy can be used in addition to irradiation in advanced stage cancers • Two agents used are Cisplatinum and 5-flourouracil (5-FU) • Cisplatin thought to sensitize cancer cells to XRT enhancing its effectiveness when used concurrently.

  18. Treatment – Advanced Stage (III/IV) • Modified or radical neck dissections are indicated in the presence of nodal disease • Neck dissections may be performed in patients with supra or subglottic T2 tumors even in the absence of nodal disease • N0 necks can have a selective dissection sparing the SCM, IJ, and XI • N1 necks usually have a modified dissection of levels II-IV

More Related